Harmony Biosciences HoldingsHRMY
Recorded

Harmony Biosciences Holdings 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 11 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member of our team will be happy to help you. Please stand by. Your meeting is about to begin. Good morning. My name is Nikki, and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences' third quarter financial results conference call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question at that time, please press star one on your telephone keypad. Please be advised that today's conference is being recorded. Lastly, if you should require operator assistance, please press star 0.

Operator

I will now turn the call over to Brennan Doyle, head of investor relations.

Brennan DoyleHead of Investor Relations

Please go ahead. Thank you, operator.

Brennan DoyleHead of Investor Relations

Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences' third quarter 2026 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our website to find the materials that accompany today's discussion. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Peter Anastasiou, Senior Executive Vice President, Chief Operating Officer, and incoming President and CEO; Adam Zaeske, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical and Scientific Officer; Steve Mollichella, Interim Principal Financial Officer. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to risk and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements even if circumstances change.

Brennan DoyleHead of Investor Relations

We encourage you to consult the risk factors referenced in our SEC filings for additional details. I would now like to turn the call over to our CEO, Dr. Jeffrey Dayno.

Jeffrey DaynoPresident and CEO

Jeff. Thank you, Brennan. Good morning, everyone, and thank you for joining our call today.

Jeffrey DaynoPresident and CEO

Before I get into the quarter, I first want to say a few words about the CEO transition we announced last month. I will be stepping down at the end of the year, and Peter Anastasiou, our Senior Executive Vice President and Chief Operating Officer, will succeed me as President and Chief Executive Officer effective January 1st, 2027. I am confident that Harmony is in very good hands with Peter, and you will hear from him next. The main themes regarding the CEO transition are continuity, strength, and growth. This leadership transition does not signal any change in our overall business or our strategic priorities. We are doing this from a position of strength and executing a well-coordinated plan.

Jeffrey DaynoPresident and CEO

Harmony continues to be a growth story, and during Q3, we moved that story forward in each of our four priorities of value creation: continue to grow WAKIX in an evolving market, advancing a novel and robust clinical-stage pipeline, transact on strategic business development deals, and protect the pitolisant franchise. I will provide some more color on our first two strategic priorities of value creation and then turn it over to Peter to expand on our other two strategic priorities. The key highlights that I want you to take away from today's call are sustained patient demand-driven growth for WAKIX in its seventh year on the market, keeping us firmly on track to exceed $1 billion in net revenue this year, and preliminary multiple ascending dose data for our orexin-2 agonist, BP-205, that further strengthen its emerging best-in-class profile. First, growing the WAKIX franchise.

Jeffrey DaynoPresident and CEO

In the third quarter, WAKIX delivered $269 million in net revenue with 400 net patient adds, resulting in approximately 9,350 average patients on WAKIX in the quarter. For the first time in company history, we expect to exceed $1 billion in revenue for WAKIX this year. We want to recognize our commercial team for their executional excellence, and Adam will take you through our commercial performance in more detail later in the call. Our second strategic priority is advancing our novel clinical-stage pipeline. The strength and durability of the pitolisant franchise gives us the flexibility to fund our pipeline, creating new growth drivers for the company. The centerpiece of our pipeline is BP-205, and we continue to have firm conviction in its best-in-class potential. Today, we announced preliminary results from the multiple ascending dose portion of our phase I study for BP-205.

Jeffrey DaynoPresident and CEO

After 14 days of once-daily dosing, the safety, tolerability, and PK profile was consistent with what we saw in the single ascending dose study, giving us confidence in the emerging best-in-class profile of BP-205. We initiated a study in sleep-deprived healthy volunteers in the third quarter, with data expected in the first quarter of 2027. Phase II studies across multiple CNS indications are planned to initiate in mid-2027. There is a clear line of sight to the multiple data catalysts for BP-205, and they are right around the corner. Kumar will provide more color on BP-205 and the rest of our pipeline programs during his R&D update. Peter will now walk you through our two other value creation priorities related to business development and protecting the pitolisant franchise.

Peter AnastasiouSenior EVP, COO, and Incoming President and CEO

Peter? Thank you, Jeff, and good morning, everyone.

Peter AnastasiouSenior EVP, COO, and Incoming President and CEO

First, I want to thank Jeff for his leadership and for everything he has done for Harmony over the last nine years. WAKIX is on track to exceed $1 billion in net revenues this year, we have a novel pipeline led by BP-205, and we have a strong balance sheet to fund our business development efforts. That is the foundation I get to build on, and I am honored to become Harmony's next CEO. Our ambition is to build Harmony into an enduring, leading CNS company with multiple products across multiple franchises, and our strategic priorities will enable us to achieve this ambition. You heard Jeff speak to our first two strategic priorities regarding our strength in the WAKIX business and the advancement of our pipeline. Our third strategic priority is transacting on business development.

Peter AnastasiouSenior EVP, COO, and Incoming President and CEO

With over $1 billion on our balance sheet, we have both the capacity and the conviction to execute on meaningful transactions. We are pursuing assets that can add near-term revenues to support our self-funded model and assets that can continue to drive long-term value creation. Our fourth strategic priority is protecting the pitolisant franchise. We have settled with six of the seven ANDA filers, and our multi-layered IP strategy across active legal proceedings reinforces our confidence in WAKIX exclusivity to March 2030, inclusive of six months of pediatric exclusivity. In summary, Harmony is a growth story, and we are executing on all four strategic priorities. To tell you more about our first strategic priority of growing the WAKIX franchise, I'll turn it over to our Chief Commercial Officer, Adam Zaeske.

Adam ZaeskeChief Commercial Officer

Adam? Thank you, Peter, and good morning, everyone.

Adam ZaeskeChief Commercial Officer

We continue to see extremely strong demand-driven growth for WAKIX this quarter. WAKIX achieved estimated average patients of 9,350, an increase of 400 patients in the quarter. WAKIX has now demonstrated a meaningful acceleration in growth in year seven on the market, with 400 net patient additions in five of the last six quarters. Prior to 2025, WAKIX had achieved 400 net patient additions only twice in the history of the brand. As a result, WAKIX delivered $269 million in net product revenue, which was right in line with our internal expectation, and we remain on track to achieve our full-year guidance of $1 billion-$1.04 billion. The drivers of this growth and performance are clear. WAKIX holds a unique position as the only non-scheduled treatment option for excessive daytime sleepiness and cataplexy in adults and pediatric patients with narcolepsy.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day